Revision history of "AAP READYNOV 2017/ATOP: Therapeutic antibodies and chronic post-operative pain" (Q3680396)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

8 October 2024

  • curprev 13:4913:49, 8 October 2024DG Regio talk contribs 58,662 bytes 0 Changed label, description and/or aliases in pt
  • curprev 13:4913:49, 8 October 2024DG Regio talk contribs 58,662 bytes +6 Set a claim value: summary (P836): O projeto ATOP (Therapeutic Antibody and Chronic Pain Post-Opertoires) é um projeto colaborativo de I&D que envolve um parceiro académico INSERM (Institut des Neurosciences de Montpellier) e um parceiro industrial (a empresa BIODOL THERAPEUTICS (PME d’Occitanie — Dpt 34). Os tratamentos atuais para a dor crónica são ineficazes (menos de 50 % dos doentes conseguem uma redução de, pelo menos, 30 % da sua dor) ou causam efeitos secundários que limitam...

23 March 2024

7 December 2023

8 June 2023

11 August 2022

  • curprev 16:2616:26, 11 August 2022DG Regio talk contribs 56,178 bytes +38,377 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

14 January 2022

13 January 2022

6 December 2021

1 December 2021

  • curprev 08:2608:26, 1 December 2021DG Regio talk contribs 11,846 bytes +1,952 Created claim: summary (P836): Das ATOP-Projekt (Therapeutische Antikörper und chronische Schmerzen nach der Operation) ist ein kooperatives R&D-Projekt, das einen akademischen Partner INSERM (Institut des Neurosciences de Montpellier) und einen Industriepartner (das Unternehmen BIODOL THERAPEUTICS (KMU von Okzitanien – Dpt 34) verbindet. Die derzeitigen Behandlungen chronischer Schmerzen schwächen die Wirksamkeit (weniger als 50 % der Patienten erreichen eine Verringerung ih...

27 November 2021

  • curprev 13:2613:26, 27 November 2021DG Regio talk contribs 9,894 bytes −1,907 Removed claim: summary (P836): Le projet ATOP (Anticorps thérapeutiques et douleurs chroniques post-Opératoires) est un projet de R&D kollaborative assoziant un partenaire académique INSERM (Institut des Neurosciences de Montpellier) et un partenaire industriel (l‚entreprise BIODOL THERAPEUTICS (PME d‘Occitanie – Dpt 34). Les traitements actuels des douleurs chroniques manquent d‚efficacité (moins de 50 % des patienten atteignent une réduction d‘au moins 30 % de leur douleu...

26 November 2021

  • curprev 23:1923:19, 26 November 2021DG Regio talk contribs 11,801 bytes +1,907 Created claim: summary (P836): Le projet ATOP (Anticorps thérapeutiques et douleurs chroniques post-Opératoires) est un projet de R&D kollaborative assoziant un partenaire académique INSERM (Institut des Neurosciences de Montpellier) et un partenaire industriel (l‚entreprise BIODOL THERAPEUTICS (PME d‘Occitanie – Dpt 34). Les traitements actuels des douleurs chroniques manquent d‚efficacité (moins de 50 % des patienten atteignent une réduction d‘au moins 30 % de leur douleur)...
  • curprev 14:5314:53, 26 November 2021DG Regio talk contribs 9,894 bytes +148 Changed label, description and/or aliases in de: translated_label

24 November 2021

18 November 2021

  • curprev 17:0817:08, 18 November 2021DG Regio talk contribs 9,315 bytes +137 Changed label, description and/or aliases in en: translated_label
  • curprev 17:0817:08, 18 November 2021DG Regio talk contribs 9,178 bytes +1,771 Created claim: summary (P836): The ATOP project (Therapeutic Antibody and Chronic Pain Post-Opertoires) is a collaborative R&D project involving an academic partner INSERM (Institut des Neurosciences de Montpellier) and an industrial partner (the company BIODOL THERAPEUTICS (PME d’Occitanie — Dpt 34). Current treatments for chronic pain are ineffective (less than 50 % of patients achieve a reduction of at least 30 % of their pain) or cause side effects limiting their use, esp...

17 November 2021